Law Firms Initiate Securities Investigations Following FDA Partial Clinical Hold on Bright Minds Biosciences

On November 2, 2026, Bright Minds Biosciences disclosed that the FDA had placed a partial clinical hold on its BMB-101 trial, citing toxicity in mice and concerns about pharmacokinetic and juvenile-toxicity data. On November 6, law firms announced investigations into potential securities claims, examining whether the company adequately disclosed the preclinical findings and data limitations to investors. Bright Minds’ stock fell significantly after the clinical-hold announcement.